Icade (XPAR:ICAD)
€ 27.56 -0.4 (-1.43%) Market Cap: 2.09 Bil Enterprise Value: 5.34 Bil PE Ratio: 0 PB Ratio: 0.41 GF Score: 65/100

Full Year 2021 Icade SA Earnings Call Transcript

Feb 21, 2022 / 09:00AM GMT
Release Date Price: €58.35 (-1.10%)
Frederic Thomas
Icade SA - Chairman of the Board

I would first like to say how pleased I am to be addressing you today albeit remotely. This full year results are an opportunity for me to recognize Icade's strong performance in 2021, which was better than we had even expected. In a complex environment with a crisis that is still ongoing, our 3 divisions have managed to do well.

As regards Office Property Investment, I have full confidence in our ability to develop our solutions and adapt to changes in the market. As far as Property Development is concerned, as you will see in a moment, everything is looking good for its continued expansion. Lastly, Icade Santé has also continued to expand at the expected pace. I feel it's important to emphasize the very high quality and diversity of its portfolio with first-time investment made in acute care and ongoing international expansion in 2021.

As such, we will further implement our strategic plan and continue along the roadmaps in place for our business lines. We have also reaffirmed our priorities for the coming years. Among these priorities

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot